TL;DR: NAD+ (nicotinamide adenine dinucleotide) is a coenzyme required for hundreds of cellular reactions, including energy metabolism and DNA repair, and its levels decline measurably with age. NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are both precursor molecules the body converts into NAD+, and both are sold as over-the-counter supplements marketed for anti-aging. Mouse studies show NMN supplementation restores NAD+ levels and improves multiple age-related physiological markers (Mills et al., Cell Metabolism, 2016). In humans, NR reliably raises blood NAD+ levels and is well tolerated in healthy older adults (Martens et al., Nature Communications, 2018), and NMN has shown similar NAD+-raising effects along with improved muscle insulin sensitivity in a small trial of prediabetic women (Yoshino et al., Science, 2021). What neither compound has demonstrated is that raising NAD+ levels translates into a longer human lifespan, slower aging, or prevention of any specific disease; the human trials to date are small, short, and focused on biomarkers rather than hard outcomes. Both supplements appear safe at studied doses over weeks to months, though long-term safety data beyond about a year is limited. This is a genuinely promising area of research with a real gap between the mechanistic story and proof of benefit.
This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making changes to your health regimen.
What Is NAD+ and Why Does It Decline With Age?
NAD+ is one of the most important molecules in cellular metabolism, acting as an electron carrier in the reactions that convert food into usable cellular energy and serving as a required substrate for several classes of enzymes, including sirtuins, which are involved in gene regulation and stress resistance, and PARPs, which repair damaged DNA. Without adequate NAD+, these processes slow down, which is why the molecule has become a central focus of aging research over the past two decades.
The decline is well documented across species, including humans, where tissue and blood NAD+ levels fall progressively from young adulthood into old age, driven by a combination of reduced synthesis and increased consumption by NAD+-degrading enzymes such as CD38, which itself becomes more active with age and with chronic inflammation (Yoshino et al., Cell Metabolism, 2018). The logic that follows is straightforward: if declining NAD+ contributes to age-related dysfunction, then restoring it with a precursor supplement might restore some of that function. That hypothesis is testable, and testing it is exactly what the NMN and NR research programs have tried to do.
What Is the Difference Between NMN and NR?
Both NMN and NR sit on the same metabolic pathway to NAD+, just at slightly different points. NR (nicotinamide riboside) is converted to NMN inside the cell by an enzyme called NRK, and NMN is then converted directly into NAD+ by another enzyme, NMNAT. NR is a smaller molecule and was the first of the two to reach human clinical trials and regulatory clarity in some markets; it is sold under trade names including Niagen and is a component of some commercial supplement brands.
NMN is the molecule popularized most heavily by longevity researcher David Sinclair's public writing and media appearances, and it has become the more commonly marketed NAD+ precursor in the general supplement market, despite entering rigorous human trials somewhat later than NR. Both are also naturally present in small quantities in foods such as broccoli, cabbage, edamame, and milk, though at doses far below what supplements provide. Neither is clearly superior to the other based on current human evidence; both raise blood NAD+ levels, and head-to-head human comparisons are limited.
What Does the Research Show About NMN?
The foundational NMN study was conducted in mice, where long-term NMN supplementation restored NAD+ levels toward youthful ranges and improved a range of age-associated measures, including insulin sensitivity, mitochondrial function, eye function, and physical activity, in older mice compared with untreated controls (Mills et al., Cell Metabolism, 2016). This paper is one of the most cited pieces of evidence in the entire NAD+ supplement conversation, and it is genuinely striking mouse data, but it remains mouse data.
Human evidence has followed more slowly. A study in healthy Japanese men found that oral NMN was well tolerated and safely raised NAD+ metabolites without significant adverse effects over a short trial period (Irie et al., Endocr J, 2020). A more clinically meaningful trial gave NMN to postmenopausal women with prediabetes over 10 weeks and found improved muscle insulin sensitivity and some improvements in insulin signaling within muscle tissue, compared with placebo, though body weight, blood pressure, and other metabolic markers were unchanged (Yoshino et al., Science, 2021). This is a real, published, peer-reviewed signal of a functional benefit in humans, not just a biomarker change, but it was a small trial (25 women), of short duration, in a specific population, and it does not establish benefit in healthy, non-prediabetic adults or in men.
What Does the Research Show About NR?
NR has a slightly longer human trial track record. A well-designed, placebo-controlled trial in healthy middle-aged and older adults found that NR supplementation was well tolerated and reliably increased blood NAD+ levels in a dose-dependent way over six weeks, but did not produce significant changes in several secondary outcomes measured, including blood pressure, arterial stiffness, and insulin sensitivity, in this generally healthy population (Martens et al., Nature Communications, 2018). That is an important, if somewhat deflating, result: NR clearly does what it is supposed to do to NAD+ levels, but the downstream functional benefits that mouse studies would predict did not clearly show up in this particular group of already-healthy people over this timeframe.
An earlier pharmacokinetic study established that oral NR is safe and effectively raises NAD+ in healthy volunteers, providing the dosing foundation later trials built on (Airhart et al., PLOS ONE, 2017). Taken together, the NR literature is more mature than the NMN literature but tells a similar overall story: reliable target engagement (NAD+ goes up), inconsistent or absent downstream functional benefit in healthy people over the trial durations studied so far.
Do NAD+ Precursors Actually Extend Lifespan?
No human trial has tested this, and none currently could, for the same reason no such trial exists for rapamycin or metformin: a lifespan trial in humans would take decades and an enormous sample size. Mouse lifespan data on NAD+ precursors is mixed and less dramatic than the rapamycin data, with some studies showing modest healthspan improvements rather than clear, large increases in maximum lifespan.
The honest current state of the science is this: NAD+ decline with age is real and well established. NMN and NR reliably raise NAD+ levels in the body, in both animals and humans, which is a genuine and replicated pharmacological effect. Whether raising NAD+ back toward youthful levels meaningfully slows human aging, prevents disease, or extends life remains unproven. The mechanistic story is more advanced than the clinical proof, which is a common pattern in longevity science and one worth remembering before treating a compelling cellular biology narrative as equivalent to demonstrated benefit. Readers interested in how researchers actually try to measure whether an intervention is working at the level of the whole organism, rather than just a single biomarker, may find our piece on measuring biological age a useful companion to this one.
Are NMN and NR Safe and Legal?
Both compounds have looked safe and well tolerated in the human trials conducted so far, typically running from several weeks to a few months, at doses in the hundreds of milligrams per day, with side effects generally limited to mild gastrointestinal symptoms in some participants. Longer-term safety data, over years rather than weeks, is limited simply because the trials have not run that long yet.
The regulatory status has been genuinely unsettled and has shifted over time. In the United States, NMN's status as a legally marketable dietary supplement has been contested after the FDA determined it had been authorized for investigation as a new drug, which under US law can preclude simultaneous marketing as a supplement; this determination has been challenged and the situation has evolved, so the legal landscape for NMN products has been in flux. NR's supplement status has generally been on firmer footing. Given this is a moving regulatory picture, checking current status and buying from reputable, third-party-tested manufacturers matters more here than for most supplements, since the market has attracted products of inconsistent quality and dosing accuracy.
Should You Take a NAD+ Precursor?
This is a legitimately personal judgment call given the current evidence, and reasonable, well-informed people land in different places. The case for trying one: the mechanism is plausible, human trials so far suggest reasonable short-term safety, NAD+ decline with age is a real and measurable phenomenon, and at least one trial found a genuine functional benefit (improved muscle insulin sensitivity) in a specific population (Yoshino et al., Science, 2021). The case for waiting: no trial has shown a clear functional benefit in generally healthy adults, long-term safety data is thin, cost is nontrivial over years of use, and the regulatory and quality-control picture, particularly for NMN, has been inconsistent.
If you are inclined to try one, treating it the way this site treats every other emerging longevity intervention makes sense: as a modest addition alongside, never instead of, the basics with the strongest mortality evidence, covered in our exercise for longevity protocol, and ideally discussed with a physician, particularly if you take other medications or have an existing condition.
Frequently Asked Questions
What is the difference between NMN and NR in terms of results? Both reliably raise blood NAD+ levels in humans, and no head-to-head human trial has clearly established one as superior to the other for functional outcomes. NMN has shown a specific benefit for muscle insulin sensitivity in prediabetic women in one trial (Yoshino et al., Science, 2021). NR has more trial history overall but has not consistently shown functional benefits beyond raising NAD+ in healthy adults (Martens et al., Nature Communications, 2018). Choosing between them currently comes down to individual preference, cost, and product quality rather than clearly superior evidence for either.
How long does it take to raise NAD+ levels with these supplements? Human trials have shown measurable increases in blood NAD+ metabolites within days to a few weeks of consistent daily dosing, with levels rising in a dose-dependent manner. What is far less clear is how long it takes, if ever, for that biochemical change to translate into a noticeable functional or health benefit, since most trials measuring functional outcomes have run only weeks to a few months.
Are NAD+ precursors the same as niacin or vitamin B3? They are related but distinct. Niacin (vitamin B3) is also a precursor that the body can convert into NAD+, and it has decades of use as a cholesterol medication at high doses, with a well-known side effect of skin flushing. NMN and NR are different molecules on the same broader biosynthetic pathway, generally marketed as not causing the flushing associated with high-dose niacin, though direct comparative trials on this specific point are limited.
Can diet alone raise NAD+ levels meaningfully? Small amounts of NMN and NR occur naturally in foods including broccoli, cabbage, cucumber, edamame, and milk, but at doses far lower than supplement forms provide, so diet alone is unlikely to meaningfully replicate the NAD+ increases seen in supplement trials. Standard healthy-aging nutrition patterns, of the kind discussed in our MIND diet and brain longevity article, remain a more evidence-backed dietary priority than trying to optimize NAD+ precursor intake through food alone.
Is it worth combining NAD+ precursors with other longevity supplements like creatine? There is no clinical trial testing this specific combination for added benefit, though the two act through different, non-competing pathways (creatine supports the phosphocreatine energy system, NAD+ precursors support redox and sirtuin-related metabolism), so there is no known mechanistic reason to avoid combining them. See our dedicated piece on creatine and longevity for the separate evidence base on that supplement, and treat any stacking decision as one to make with awareness that neither has proven lifespan benefits on its own yet.